Dr Byong Seung Cho, the developer of ASCEplus technology, visits Wellclinic in Warsaw

On 28 September 2026, a special meeting took place in Warsaw, attended by Dr Byong Seung Cho – a scientist specialising in molecular biology, founder and CEO of the South Korean biotechnology company ExoCoBio, and developer of the technology ASCEplus. It was his first visit to Warsaw, and Wellclinic It was the only medical facility in Poland that was situated along the route of his visit.

The meeting brought together the developer of ASCEplus technology, the Wellclinic team of specialists, representatives of the clinic and patients undergoing therapy using ASCEplus products. It was a unique opportunity for direct discussion, the exchange of experiences and an insight into developments exosomal technologies from several different perspectives.

Dr Byong Seung Cho at Wellclinic

During his visit, Dr Byong Seung Cho met with by Krzysztof Reinhard, founder and CEO of Wellclinic, together with a team of specialists and the clinic’s patients. The meeting was of particular significance to Wellclinic, because ASCEplus technology is used in the treatments carried out at the clinic. The direct conversation with the developer of the technology provided an opportunity to exchange experiences, discuss observations to date and talk about the future direction of modern regenerative therapies.

Doctors and beauticians at the Clinic use ASCEplus in individually tailored therapies aimed at regenerating and improving the condition of the skin and hair. A direct conversation with the developer of the technology provided an opportunity to share experiences of its practical application and to discuss the potential for further development of modern regenerative therapies.

One of the key topics of the meeting was Wellclinic’s experience of working with patients and the team’s observations regarding the use of ASCEplus solutions. The interview also provided an opportunity to look at the technology from the perspective of its creator and to learn about the directions in which solutions based on exosomal technologies are being developed.

Why Wellclinic, of all places?

Dr Byong Seung Cho’s visit to Wellclinic was linked to the clinic’s experience in utilising modern biotechnological solutions. Wellclinic combines advanced technologies, specialist expertise, a personalised approach to each patient and a commitment to the safety of the treatments provided.

One of the areas the clinic has been consistently developing is regenerative medicine, including the use of modern exosomal technologies in therapy treatment of alopecia and in facial rejuvenation treatments. The use of ASCEplus in clinical practice is one aspect of this approach.

Wellclinic’s position in the market is also confirmed by numerous awards and recognition from patients. The clinic has been nominated for Global Health Care Award 2026, and also came first w the 2026 ranking of the best aesthetic medicine clinics in Poland.

It is precisely this combination of technology, specialist expertise and a personalised approach to the patient that has made the appointment with the creator of ASCEplus was of particular importance to Wellclinic.

A meeting of three perspectives

Visit by Dr Byong Seung Cho The event at Wellclinic provided an opportunity for three different perspectives to come together – the developer of ASCEplus technology and a researcher specialising in molecular biology, Wellclinic specialists who use this technology in their day-to-day practice, and patients undergoing therapy using ASCEplus products.

For the Wellclinic team, the meeting provided an opportunity to discuss first-hand their experiences of using ASCEplus, the observed results of the therapy, and future directions in exosome technology. Dr Byong Seung Cho had the opportunity to learn about the experiences of specialists who work with the technology on a daily basis, as well as the perspectives of patients undergoing therapies based on ASCEplus products.

A discussion on the potential of regenerative medicine

Exosomes These are areas of intensive research in the field of regenerative medicine. Scientists are investigating their potential applications, including in the context of skin regeneration, improving skin condition and enhancing the function of the skin barrier.

The meeting at Wellclinic was therefore not only an opportunity to discuss experiences to date, but also to exchange knowledge on the future directions of exosomal technology and its potential applications in modern therapies.

„It is a great honour for us that Byong Seung Cho chose to visit Wellclinic. As a clinic, we use ASCEplus products in our patients’ treatments, which is why his visit was a unique opportunity for us to discuss first-hand our experiences of using them, the results observed, and the future direction of exosomal technology. We were particularly pleased to be able to bring together three perspectives – that of the technology’s developer, our specialists, and the patients who benefit from these therapies.” Quantum Face, which utilises exosomes. ”Above all, we wanted this to be a meaningful and substantive meeting,” says Brygida Kasperowicz, Master-level Beautician at Wellclinic.

Equally important was Wellclinic’s management and development outlook. Krzysztof Reinhard emphasised the importance of direct contact with the developers of the technology and the exchange of experiences as key elements in the clinic’s informed development.

„The development of modern medicine requires not only access to innovative technologies, but also knowledge, experience and a responsible approach to their use. The meeting with Dr Byong Seung Cho gave us the opportunity to discuss the ASCEplus technology directly, its development and our experiences of using it in practice. Such meetings are an important part of shaping the direction in which we are developing Wellclinic,” says Krzysztof Reinhard, founder and CEO of Wellclinic.

Sharing experiences to support the development of therapies and technologies

Dr Byong Seung Cho’s visit was part of Wellclinic’s development as a clinic that combines modern technology, specialist expertise and a personalised approach to each patient.

One of the areas that Wellclinic continues to develop is regenerative medicine, including therapies that harness the potential of exosomal technology. The use of ASCEplus in clinical practice is part of this trend and a response to the growing interest in solutions that support the regenerative processes of the skin and hair.

Direct exchange of experiences with the creator of ASCEplus It was an important step for Wellclinic in terms of its further development and raising the standards of the therapies it provides. The meeting provided an opportunity not only to discuss experiences of using the technology in clinical practice, but also to hear the developer’s perspective on the future development of exosomal solutions.

A special event at Wellclinic

Visit Dr Byong Seung Cho at Wellclinic It was an important event for the entire clinic team. It brought together the worlds of science and biotechnology with clinical practice, creating a space for the direct exchange of knowledge and experience.

A meeting between the developer of the ASCEplus technology, specialists from Wellclinic, representatives of the board of directors and patients highlighted just how many possibilities can accompany the development of modern therapies.

For Wellclinic, it was, above all, a substantive discussion about the technology, experiences of using it, and its applicability modern regenerative medicine. It also provided an opportunity to highlight the importance of cooperation, the exchange of knowledge and the ongoing search for new solutions to support the development of modern patient care.